Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of "Buy" by Analysts

Key Points

• Voyager Therapeutics, Inc. has received an average recommendation of "Buy" from eight analysts, with a one-year price target averaging $13.39.
• Institutional investors have increased their stakes in Voyager Therapeutics, with Allspring Global Investments growing its position by 53.8% in the first quarter of the year.
• The company's stock is currently trading at $3.20, down 2.1%, and it reported a significant earnings miss with a loss of ($0.53) per share in its last quarterly report.

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have earned an average recommendation of "Buy" from the eight brokerages that are covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $13.39.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, April 8th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN grew its stake in shares of Voyager Therapeutics by 3.7% in the fourth quarter. Wells Fargo & Company MN now owns 66,718 shares of the company's stock worth $378,000 after purchasing an additional 2,400 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Voyager Therapeutics by 133.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock valued at $31,000 after buying an additional 3,077 shares in the last quarter. Privium Fund Management B.V. boosted its stake in Voyager Therapeutics by 16.6% during the second quarter. Privium Fund Management B.V. now owns 25,241 shares of the company's stock valued at $79,000 after buying an additional 3,596 shares in the last quarter. Geode Capital Management LLC boosted its stake in Voyager Therapeutics by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company's stock valued at $6,149,000 after buying an additional 4,729 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Voyager Therapeutics during the fourth quarter valued at about $29,000. Institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Stock Down 7.2%

Shares of VYGR traded down $0.23 during trading on Wednesday, reaching $2.96. The company's stock had a trading volume of 873,160 shares, compared to its average volume of 642,179. The company has a fifty day moving average of $3.19 and a two-hundred day moving average of $3.71. Voyager Therapeutics has a twelve month low of $2.64 and a twelve month high of $8.53. The company has a market cap of $163.81 million, a price-to-earnings ratio of -2.03 and a beta of 0.90.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.18). The firm had revenue of $6.47 million for the quarter, compared to analyst estimates of $13.55 million. Voyager Therapeutics had a negative net margin of 126.49% and a negative return on equity of 27.36%. As a group, equities analysts forecast that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.